Latest Medizintechnik AG Stories
BERLIN, January 21, 2011 /PRNewswire-FirstCall/ -- Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission.
BERLIN, November 23, 2010 /PRNewswire-FirstCall/ -- Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a company specializing in special compounds for the diagnosis and treatment of cancer, via its subsidiary company Eckert & Ziegler f-con Deutschland GmbH closed an exclusive sales agreement with the Karlsruhe-based ZAG Zyklotron AG for the regular delivery of Fluorodeoxyglucose (18F) (FDG).
NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Brachytherapy http://www.reportlinker.com/p0131245/Brachytherapy.html This report analyzes the Global Market for Brachytherapy in Millions of US$.